Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › A Randomized, Open-label Trial Comparing Methadone and Levo-Alpha-Acetylmethadol (LAAM) in Maintenance Treatment of Opioid Addiction

Publication

A Randomized, Open-label Trial Comparing Methadone and Levo-Alpha-Acetylmethadol (LAAM) in Maintenance Treatment of Opioid Addiction

Wolstein, Jörg; Gastpar, M.; Finkbeiner, T.; u. a. (2009): A Randomized, Open-label Trial Comparing Methadone and Levo-Alpha-Acetylmethadol (LAAM) in Maintenance Treatment of Opioid Addiction, in: Pharmacopsychiatry : clinical pharmacology, psychiatry, psychology, neurophysiology, neurobiology, gerontopsychiatry ; official organ of Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Stuttgart - New York: Georg Thieme Verlag KG, Jg. 42, Nr. 1, S. 1–8, doi: 10.1055/s-0028-1083818.

Details

Faculty/Chair
Author
Gastpar, M.
Finkbeiner, T.
Heinrich, C.
Heitkamp, R.
Poehlke, T.
Scherbaum, N.
Title of the Journal
Pharmacopsychiatry : clinical pharmacology, psychiatry, psychology, neurophysiology, neurobiology, gerontopsychiatry ; official organ of Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP)
ISSN
1439-0795
Publisher Information
Georg Thieme Verlag KG : Stuttgart - New York
Year of publication
2009
Volume
42
Issue
1
Language
English
DOI
Abstract

Introduction: Levo-Alpha-Acetylmethadol (LAAM) is a synthetic opioid analgesic with μ-agonistic activity and a long duration of action. There are several, almost exclusively US American studies showing the efficacy of LAAM as a maintenance drug which has the advantage that it needs to be administered only three times a week. LAAM is currently not marketed in EU countries due to cardiac complications. We report on the first European multi-center, parallel group, flexible dose, open-label, randomized clinical trial comparing LAAM and methadone in patients with opioid dependence.

Methods: Eighty-four opioid addicts in ongoing maintenance treatment with stable methadone doses were treated with methadone under study conditions for 5 weeks (run-in phase), then randomly assigned to a methadone (n=41) or a LAAM (n=43) group. Study duration was 24 weeks after randomization. Objective measures (drug urine screenings, retention rate), subjective measures (symptoms of withdrawal and craving, report of substance use), and safety data were collected weekly. The main outcome criterion was the number of opiate-free urine samples per number of weeks of study participation.

Results: Non-inferiority was shown for LAAM compared to methadone. Both substances were well tolerated. There were no clinical cardiac complications in either group.

Discussion: Our study confirmed the results of previous investigations with LAAM as being efficacious and well tolerated in opioid dependence. A discussion to reconsider the availability of LAAM is recommended.

Type
Article
URI
Activation date
2018-11-09, 2018-11-09

Permalink: https://fis.uni-bamberg.de/handle/uniba/44650 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.